Cargando…
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
BACKGROUND: The nine-valent human papillomavirus (9vHPV) vaccine protects against infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal 36-month Phase III immunogenicity study of 9vHPV vaccine in 9- to 15-year-old girls and boys was extended to assess long-ter...
Autores principales: | Olsson, Sven-Eric, Restrepo, Jaime Alberto, Reina, Julio Cesar, Pitisuttithum, Punnee, Ulied, Angels, Varman, Meera, Van Damme, Pierre, Moreira, Edson Duarte, Ferris, Daron, Block, Stanley, Bautista, Oliver, Gallagher, Nancy, McCauley, Jennifer, Luxembourg, Alain |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396911/ https://www.ncbi.nlm.nih.gov/pubmed/32659510 http://dx.doi.org/10.1016/j.pvr.2020.100203 |
Ejemplares similares
-
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
por: Kjaer, Susanne K., et al.
Publicado: (2020) -
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
por: Petersen, Lone K., et al.
Publicado: (2017) -
Rumination in a Boy of Nine Years
por: Peter, Luther C.
Publicado: (1899) -
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
por: Thiem, Vu Dinh, et al.
Publicado: (2021) -
Needle urethral self-insertion for nine years in an adolescent boy
por: Wang, Song, et al.
Publicado: (2021)